Pathophysiology of Bone Disorders and Osteoporosis Flashcards

1
Q

what happens to bones as we age?

A

they become thinner and weaker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is Wolff’s law?

A

Every change in function of bone is followed by certain definite changes in its internal architecture and its external conformation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how does the parathyroid hormone regulate calcium?

A

it increases calcium levels by:

  1. Stimulating osteoclasts to degrade bone and release Ca2+ into blood
  2. Increasing intestinal absorption of calcium
  3. Decreases calcium excretion at kidneys
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is secreted from the thyroid gland to reduce calcium ion levels and how does it do this?

A

Calcitonin is secreted and it reduces calcium ion levels by:

  1. inhibiting osteoclast activity
  2. increasing calcium excretion at kidneys
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what effect does a rise in blood calcium have on the thyroid gland to then reduce calcium levels?

A

It triggers the thyroid to release calcitonin which then stimulates Ca2+ salt deposit in bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the most common cause of Rickets/Osteomalacia?

A

severe, prolonged vitamin D deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is the pathogenesis of rickets?

A
  1. normal bone is formed

2. the body can not fully mineralize the newly formed osteoid tissue, resulting in decreased bone strength

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how is rickets treated?

A

with high-doses of vitamin D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the main areas affected by Paget’s disease?

A

skull, spine, pelvis, femur, and tibia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the pathogenesis of Paget’s disease?

A
  • An accelerated bone formation does not allow for proper layering of collagen leading to disorganized or woven collagen.
  • this causes reduced mineralization causing spotty weakening of bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how is Paget’s disease treated?

A
  • Bisphosphonates as they work directly on osteoclasts to slow down bone turnover, allowing more time for proper bone formation
  • Subcutaneous or intramuscular calcitonin can be used if bisphosphonates therapy is contraindicated.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

which two hormones help maintain bone mass to prevent osteoporosis?

A

Estrogens and androgens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is postmenopausal osteoporosis (type I)?

A

When oestrogen deficiency causes:
• increased proliferation and activation of osteoclasts
• prolongs survival of osteoclasts
Therefore more bone breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is senile osteoporosis (type II)?

A

Bone loss due to:
• increased bone turnover
• Malabsorption
• Mineral and vitamin deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is used to diagnose osteoporosis?

A

Bone mineral density (BMD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

where are Bone mineral density (BMD) measurements usually taken?

A

at lumbar spine and hip

17
Q

what does a T score between -1 and -2.5 indicate?

A

osteopenia

18
Q

what does a T score equal to or less than -2.5 indicate?

A

osteoporosis

19
Q

what does a T score less than -2.5 with a fracture indicate?

A

established osteoporosis

20
Q

what is the active form of vitamin D?

A

1,25-(OH)2-D = calcitriol

21
Q

where is RANKL released from and what does it do?

A
  • secreted by osteoblasts and bone marrow stromal cells

- mediates osteoclast differentiation, activation, and survival and primary mediator of bone resorption.

22
Q

what does Osteoprotegerin (OPG) do?

A

provides alternative binding site for RANKL acting as decoy receptor, so it cannot activate osteoclast cellular signalling preventing bone resorption/breakdown